WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 526940
Description: YM-430, also known as YM-15430; YM-154301; is a dual of β1 adrenergic receptor antagonist and calcium channel antagonist. YM430 could be both an antianginal and antihypertensive agent, because of its dual activities. YM430 (10(-8)-10(-6) M) inhibited 3,4-diaminopyridine-induced rhythmic contractions with an IC50 value of 59.2 nM. In anesthetized rats, YM430 (10-100 mg/kg PO) inhibited arginine vasopressin-induced ST-segment depression with an IC50 value of 36.6 mg/kg PO. YM430 may be of value in the treatment of various types of angina pectoris such as variant and stable angina.
MedKoo Cat#: 526940
Chemical Formula: C29H35N3O8
Exact Mass: 553.2424
Molecular Weight: 553.612
Elemental Analysis: C, 62.92; H, 6.37; N, 7.59; O, 23.12
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: YM-15430; YM-154301; YM-15430-1; YM-15430-2; YM-15430-3; YM430; YM-430; YM 430.
IUPAC/Chemical Name: 3-(4-(((S)-2-hydroxy-3-phenoxypropyl)amino)butyl) 5-methyl (S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
InChi Key: HBXMSJLNXYLVTA-HOFKKMOUSA-N
InChi Code: InChI=1S/C29H35N3O8/c1-19-25(28(34)38-3)27(21-10-9-11-22(16-21)32(36)37)26(20(2)31-19)29(35)39-15-8-7-14-30-17-23(33)18-40-24-12-5-4-6-13-24/h4-6,9-13,16,23,27,30-31,33H,7-8,14-15,17-18H2,1-3H3/t23-,27-/m0/s1
SMILES Code: O=C(C1=C(C)NC(C)=C(C(OCCCCNC[C@H](O)COC2=CC=CC=C2)=O)[C@H]1C3=CC=CC([N+]([O-])=O)=C3)OC
Appearance: White to off-white solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 553.612 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Sasaki S, Nakagawa M. [Calcium channel blocker for therapy of patients with hypertension]. Nihon Rinsho. 1997 Aug;55(8):2061-6. Review. Japanese. PubMed PMID: 9284424.
2: Shibasaki K, Arai Y, Uchida W, Okazaki T, Asano M, Takenaka T. Antianginal effects of YM430, a novel calcium entry-blocking and beta-adrenoceptor-blocking agent in several experimental angina models. Gen Pharmacol. 1997 Oct;29(4):545-50. PubMed PMID: 9352300.
3: Shibasaki K, Uchida W, Takizawa K, Masuda N, Okazaki T, Inagaki O, Asano M, Takenaka T. Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6. PubMed PMID: 9084878.
4: Shibasaki K, Takizawa K, Uchida W, Takenaka T. Hypotensive effects of YM430, a 1,4-dihydropyridine derivative, in spontaneously hypertensive rats and renal hypertensive dogs. Jpn J Pharmacol. 1997 Feb;73(2):113-24. PubMed PMID: 9074945.